Equities research analysts forecast that Biodel Inc. (NASDAQ:ALBO) will announce earnings of ($0.85) per share for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Biodel’s earnings, with the highest EPS estimate coming in at ($0.76) and the lowest estimate coming in at ($1.00). The company is scheduled to issue its next earnings report on Monday, January 1st.
On average, analysts expect that Biodel will report full-year earnings of ($3.69) per share for the current financial year, with EPS estimates ranging from ($4.09) to ($3.38). For the next financial year, analysts forecast that the company will post earnings of ($3.43) per share, with EPS estimates ranging from ($4.60) to ($2.65). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that cover Biodel.
Biodel (NASDAQ:ALBO) last released its earnings results on Monday, August 21st. The biopharmaceutical company reported ($0.86) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.84) by ($0.02).
Several analysts have commented on ALBO shares. Wedbush started coverage on shares of Biodel in a research note on Friday, June 30th. They issued an “outperform” rating on the stock. Needham & Company LLC started coverage on shares of Biodel in a research note on Tuesday, July 18th. They issued a “buy” rating and a $35.00 price target on the stock. Zacks Investment Research cut shares of Biodel from a “buy” rating to a “hold” rating in a research note on Tuesday, August 1st. Cowen and Company started coverage on shares of Biodel in a research note on Wednesday, August 16th. They issued an “outperform” rating on the stock. Finally, ValuEngine cut shares of Biodel from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $40.33.
Biodel (NASDAQ ALBO) traded down 0.46% on Friday, reaching $23.99. The company had a trading volume of 12,904 shares. Biodel has a 12-month low of $14.00 and a 12-month high of $37.69. The stock’s 50 day moving average price is $22.90 and its 200-day moving average price is $22.25. The stock’s market capitalization is $213.08 million.
A hedge fund recently raised its stake in Biodel stock. Renaissance Technologies LLC lifted its holdings in Biodel Inc. (NASDAQ:ALBO) by 0.5% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 149,632 shares of the biopharmaceutical company’s stock after buying an additional 794 shares during the period. Renaissance Technologies LLC’s holdings in Biodel were worth $3,591,000 at the end of the most recent reporting period. Institutional investors own 27.36% of the company’s stock.
WARNING: “Biodel Inc. (ALBO) Expected to Post Earnings of -$0.85 Per Share” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.tickerreport.com/banking-finance/2956083/biodel-inc-albo-expected-to-post-earnings-of-0-85-per-share.html.
Biodel Inc is a specialty biopharmaceutical company. The Company focuses on the development and commercialization of treatments for diabetes. The Company is engaged in developing product candidates by applying its formulation technologies to existing drugs. The Company is engaged in developing room temperature stable glucagon presentations for use as a rescue treatment for diabetes patients experiencing severe hypoglycemia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biodel Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biodel Inc. and related companies with MarketBeat.com's FREE daily email newsletter.